RESISTANCE : EFFECTIVENESS OF CURRENT INTERVENTIONS —

There is a demonstrated link between antibiotic resistance and the overuse of antibiotics. In addition, antibiotic misuse, such as the use of an inappropriate antibiotic or patients failing to complete their therapy, may also promote antibiotic resistance. Strategies are needed to tackle current and expected levels of resistance and to slow the development of antibiotic resistance. The 2 main strategies to address resistance are the development of new antibiotics that target resistant bacteria and better clinical practice. To encourage pharmaceutical companies to develop new antibiotics, it will be necessary to use economic incentives, such as the Bioshield 2 “wild card” scheme, and improve the regulatory environment. Better clinical practice includes improved diagnosis of bacterial and viral infections; use of the appropriate antibiotics in situations in which there is proven benefit, through the use of guidelines or protocols; and promotion of patient compliance. Vaccine may be an effective strategy for some resistant organisms. The 7valent pneumococcal conjugate vaccine has had a major effect in reducing resistant pneumococcal infections in children, and herd immunity has helped protect unvaccinated children and adults. However, there are still concerns about increases in disease caused by nonvaccine serotypes, particularly 19A, which mean that appropriate antibiotic use programs are still vital. (Adv Stud Med. 2006;6(7C):S659-S666)

[1]  C. Whitney,et al.  Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. , 2005, The Journal of infectious diseases.

[2]  Xinhua Yu,et al.  Declining invasive pneumococcal disease in the U.S. elderly. , 2005, Vaccine.

[3]  E. Claas,et al.  Improved Diagnosis of the Etiology of Community-Acquired Pneumonia with Real-Time Polymerase Chain Reaction , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Richter,et al.  Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  D. Livermore,et al.  Minimising antibiotic resistance. , 2005, The Lancet. Infectious diseases.

[6]  A. Schuchat,et al.  Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment , 2005, The Lancet.

[7]  A. Schilder,et al.  Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  B. LaFleur,et al.  Population-Based Impact of Pneumococcal Conjugate Vaccine in Young Children , 2004, Pediatrics.

[9]  W. Schaffner,et al.  Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  E. Lewis,et al.  Postlicensure Surveillance for Pneumococcal Invasive Disease After Use of Heptavalent Pneumococcal Conjugate Vaccine in Northern California Kaiser Permanente , 2004, The Pediatric infectious disease journal.

[11]  S. Kaplan,et al.  Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. , 2004, Pediatrics.

[12]  S. Madhi,et al.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. , 2003, The New England journal of medicine.

[13]  K. O'Brien,et al.  Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial , 2003, The Lancet.

[14]  R. Dagan,et al.  Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings , 2003, The Pediatric infectious disease journal.

[15]  Marc Lipsitch,et al.  Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States , 2003, Nature Medicine.

[16]  R. Dagan,et al.  Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. , 2002, The Journal of infectious diseases.

[17]  S. Obaro,et al.  Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants , 2000, The Pediatric infectious disease journal.

[18]  R. Huebner,et al.  Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. , 1999, The Journal of infectious diseases.

[19]  R. Dagan,et al.  Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. , 1997, The Pediatric infectious disease journal.

[20]  D. Greenberg,et al.  Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. , 1996, The Journal of infectious diseases.

[21]  S. Obaro,et al.  Carriage of pneumococci after pneumococcal vaccination , 1996, The Lancet.